Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3

Transplant Proc. 2001 Feb-Mar;33(1-2):1057-8. doi: 10.1016/s0041-1345(00)02414-3.

Authors

S Chowdhury¹, R K Kode, K Ranganna, A M Damask, A Lam, B Fyfe, S Stabler, A M Kumar, M B Tomeny, M S Kumar, O Pankewycz

Affiliation

¹ Division of Transplantation, MCP Hahnemann University, Philadelphia, PA, USA.

PMID: 11267189
DOI: 10.1016/s0041-1345(00)02414-3

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Basiliximab
Cyclosporine / administration & dosage*
Glucocorticoids / therapeutic use*
Graft Rejection / prevention & control
Humans
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology*
Methylprednisolone Hemisuccinate / therapeutic use*
Muromonab-CD3 / therapeutic use*
Mycophenolic Acid / analogs & derivatives
Mycophenolic Acid / therapeutic use*
Recombinant Fusion Proteins*
Remission Induction

Substances

Antibodies, Monoclonal
Glucocorticoids
Immunosuppressive Agents
Muromonab-CD3
Recombinant Fusion Proteins
Methylprednisolone Hemisuccinate
Cyclosporine
Basiliximab
Mycophenolic Acid